IPRIFLAVONE: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Ipriflavone is made in the laboratory from a compound found in the soy plant. In some countries, ipriflavone is available as a prescription. In the United States, ipriflavone is considered a dietary supplement.

Ipriflavone is used for weak and brittle bones (osteoporosis) and for a bone disease that causes pain (Paget disease). Ipriflavone is also used by bodybuilders, but there is no good scientific evidence to support this use.

How does it work ?

Ipriflavone can block part of the process that leads to bone loss.

Uses & Effectiveness

Likely Effective for

Weak and brittle bones (osteoporosis). Taking ipriflavone with calcium daily can prevent bone loss in postmenopausal women with osteoporosis. There is some evidence that it might actually increase bone strength in some of these women, and it also seems to decrease pain from osteoporosis. Taking ipriflavone with estrogen also seems to prevent osteoporosis and increase bone strength in older women. Adding calcium might make this combination work even better.

Possibly Effective for

A bone disease that can cause pain (Paget disease). Early research shows that taking ipriflavone might decrease bone pain in some people with Paget disease.

Insufficient Evidence for

A bone disorder that occurs in people with kidney disease (renal osteodystrophy).
Food allergies.
Increasing metabolism in bodybuilders.
Stroke.
Other conditions.

More evidence is needed to rate the effectiveness of ipriflavone for these uses.

Side Effects

When taken by mouth: Ipriflavone is LIKELY SAFE for most people when used with proper medical supervision. There is concern that ipriflavone can cause a decreased white blood cell count (lymphocytopenia) in people taking it for greater than six months.

Special Precautions and Warnings

Pregnancy and breast-feeding: There isn't enough reliable information to know if ipriflavone is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.

Weak immune system: Ipriflavone can lower the body's white blood cell count, making it more difficult for the body to fight off infection. This is especially concerning in people who already have a weak immune system due to AIDS, drugs used to prevent organ rejection after transplant, chemotherapy, or other causes. If you have a weak immune system, check with your healthcare provider before starting ipriflavone.

Interactions

Moderate Interaction

Be cautious with this combination

Medications changed by the liver (Cytochrome P450 1A2 (CYP1A2) substrates) interacts with IPRIFLAVONE
Some medications are changed and broken down by the liver. Ipriflavone might decrease how quickly the liver breaks down some medications. Taking ipriflavone along with some medications that are changed by the liver might increase the effects and side effects of some medications. Before taking ipriflavone, talk to your healthcare provider if you take any medications that are changed by the liver.

Some of these medications that are changed by the liver include clozapine (Clozaril), cyclobenzaprine (Flexeril), fluvoxamine (Luvox), haloperidol (Haldol), imipramine (Tofranil), mexiletine (Mexitil), olanzapine (Zyprexa), pentazocine (Talwin), propranolol (Inderal), tacrine (Cognex), theophylline, zileuton (Zyflo), zolmitriptan (Zomig), and others.
Medications changed by the liver (Cytochrome P450 2C9 (CYP2C9) substrates) interacts with IPRIFLAVONE
Some medications are changed and broken down by the liver. Ipriflavone might decrease how quickly the liver breaks down some medications. Taking ipriflavone along with some medications that are broken down by the liver can increase the effects and side effects of some medications. Before taking ipriflavone, talk to your healthcare provider if you take any medications that are changed by the liver.

Some medications that are changed by the liver include amitriptyline (Elavil), diazepam (Valium), zileuton (Zyflo), celecoxib (Celebrex), diclofenac (Voltaren), fluvastatin (Lescol), glipizide (Glucotrol), ibuprofen (Advil, Motrin), irbesartan (Avapro), losartan (Cozaar), phenytoin (Dilantin), piroxicam (Feldene), tamoxifen (Nolvadex), tolbutamide (Tolinase), torsemide (Demadex), warfarin (Coumadin), and others.
Medications that decrease the immune system (Immunosuppressants) interacts with IPRIFLAVONE
Ipriflavone might decrease the immune system. Taking ipriflavone along with other medications that decrease the immune system might decrease the immune system too much. Avoid taking ipriflavone with medications that decrease the immune system.

Some medications that decrease the immune system include azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf), sirolimus (Rapamune), prednisone (Deltasone, Orasone), corticosteroids (glucocorticoids), and others.
Theophylline interacts with IPRIFLAVONE
The body breaks down theophylline to get rid of it. Ipriflavone might decrease how quickly the body gets rid of theophylline. Taking ipriflavone along with theophylline might increase the effects and side effects of theophylline.

Dosing

The following doses have been studied in scientific research:

BY MOUTH:

For weak and brittle bones (osteoporosis): 200 mg of ipriflavone three times daily.
For a bone disease that can cause pain (Paget disease): 600-1200 mg of ipriflavone daily.

View References

REFERENCES:

Allen CT and Peden-Adams MM. Subchronic Exposure to Ellagic Acid Impairs Cytotoxic T-Cell Function and Supresses Humoral Immunity in Mice. Immunopharmacology & Immunotoxicology 2003;25(3):409.

Bagchi, D., Roy, S., Patel, V., He, G., Khanna, S., Ojha, N., Phillips, C., Ghosh, S., Bagchi, M., and Sen, C. K. Safety and whole-body antioxidant potential of a novel anthocyanin-rich formulation of edible berries. Mol.Cell Biochem. 2006;281(1-2):197-209. View abstract.

Beekwilder, J., Hall, R. D., and de Vos, C. H. Identification and dietary relevance of antioxidants from raspberry. Biofactors 2005;23(4):197-205. View abstract.

Beekwilder, J., Jonker, H., Meesters, P., Hall, R. D., van, der Meer, I, and Ric, de, V. Antioxidants in raspberry: on-line analysis links antioxidant activity to a diversity of individual metabolites. J Agric.Food Chem 5-4-2005;53(9):3313-3320. View abstract.

Cavanagh, H. M., Hipwell, M., and Wilkinson, J. M. Antibacterial activity of berry fruits used for culinary purposes. J Med Food 2003;6(1):57-61. View abstract.

de Ancos, B., Ibanez, E., Reglero, G., and Cano, M. P. Frozen storage effects on anthocyanins and volatile compounds of raspberry fruit. J Agric.Food Chem. 2000;48(3):873-879. View abstract.

Gudej, J. Kaempferol and quercetin glycosides from Rubus idaeus L. Leaves. Acta Poloniae Pharmaceutica - Drug Research (Poland) 2003;60:313-315.

Hakkinen, S. H., Karenlampi, S. O., Mykkanen, H. M., and Torronen, A. R. Influence of domestic processing and storage on flavonol contents in berries. J Agric.Food Chem 2000;48(7):2960-2965. View abstract.

Kowalczyk, E., Krzesinski, P., Fijalkowski, P., Blaszczyk, J., and Kowalski, J. [The use of anthocyanins in the treatment of cardiovascular diseases]. Pol.Merkuriusz.Lek. 2005;19(109):108-110. View abstract.

Liu, M., Li, X. Q., Weber, C., Lee, C. Y., Brown, J., and Liu, R. H. Antioxidant and antiproliferative activities of raspberries. J Agric.Food Chem 5-8-2002;50(10):2926-2930. View abstract.

Morillas-Ruiz, J., Zafrilla, P., Almar, M., Cuevas, M. J., Lopez, F. J., Abellan, P., Villegas, J. A., and Gonzalez-Gallego, J. The effects of an antioxidant-supplemented beverage on exercise-induced oxidative stress: results from a placebo-controlled double-blind study in cyclists. Eur J Appl Physiol 2005;95(5-6):543-549. View abstract.

Mullen, W., Lean, M. E., and Crozier, A. Rapid characterization of anthocyanins in red raspberry fruit by high-performance liquid chromatography coupled to single quadrupole mass spectrometry. J Chromatogr.A 8-9-2002;966(1-2):63-70. View abstract.

Agnusdei D, Zacchei F, Bigazzi S, et al. Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis. Drugs Exp Clin Res 1989;15:97-104. View abstract.

Alexandersen P, Toussaint A, Christiansen C, et al. Ipriflavone in the treatment of postmenopausal osteoporosis: A randomized controlled trial. JAMA 2001;285:1482-8. View abstract.

Arjmandi BH, Birnbaum RS, Juma S, et al. The synthetic phytoestrogen, ipriflavone, and estrogen prevent bone loss by different mechanisms. Calcif Tissue Int 2000;66:61-5. View abstract.

Gambacciani M, Cappagli B, Piaggesi L, et al. Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists. Calcif Tissue Int 1997;61:S15-8. View abstract.

Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women. Maturitas 1997;28:75-81. View abstract.

Gennari C, Adami S, Agnusdei D, et al. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass. Calcif Tissue Int 1997;61,Suppl 1:S19-22. View abstract.

Gennari C, Agnusdei D, Crepaldi G, et al. Effect of ipriflavone-a synthetic derivative of natural isoflavones-on bone mass loss in the early years after menopause. Menopause 1998;5:9-15. View abstract.

Head KA. Ipriflavone: an important bone-building isoflavone. Altern Med Rev 1999;4:10-22. View abstract.

Hu Q, Long C, Wu D, et al. The efficacy and safety of ipriflavone in postmenopausal women with osteopenia or osteoporosis: A systematic review and meta-analysis. Pharmacol Res. 2020;159:104860. View abstract.

Hyodo T, Ono K, Koumi T, et al. A study of the effects of ipriflavone administration on hemodialysis patients with renal osteodystrophy: preliminary report. Nephron 1991;58:114-5.

Masilamani M, Chang LM, Kamalakannan M, et al. Dietary isoflavone supplementation for food allergy: A pilot study. J Allergy Clin Immunol Pract. 2017;5(6):1760-2.e4. doi: 10.1016/j.jaip.2017.04.005. View abstract.

Maugeri D, Panebianco P, Russo MS, et al. Ipriflavone-treatment of senile osteoporosis: results of a multicenter, double-blind clinical trial of 2 years. Arch Gerontol Geriatr 1994;19:253-63.

Melis GB, Paoletti AM, Bartolini R, et al. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium. Bone Miner 1992;19,Suppl 1:S49-56. View abstract.

Melis GB, Paoletti AM, Cagnacci A, et al. Lack of any estrogenic effect of ipriflavone in postmenopausal women. J Endocrinol Invest 1992;15:755-61. View abstract.

Monostory K, Vereczkey L, Levai F, et al. Ipriflavone as an inhibitor of human cytochrome P450 enzymes. Br J Pharmacol 1998;123:605-10. View abstract.

Nie R, Lu J, Xu R, et al. Ipriflavone as a non-steroidal glucocorticoid receptor antagonist ameliorates diabetic cognitive impairment in mice. Aging Cell 2022;21(3):e13572. View abstract.

Nozaki M, Hashimoto K, Inoue Y, et al. Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen. Int J Gynaecol Obstet 1998;62:69-75. View abstract.

Ohta H, Komukai S, Makita K, et al. Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass. Horm Res 1999;51:178-83. View abstract.

Petilli M, Fiorelli G, Benvenuti S, et al. Interactions between ipriflavone and the estrogen receptor. Calcif Tissue Int 1995;56:160-5. View abstract.

Scali G, Mansanti P, Zurlo A, et al. Analgesic effect of ipriflavone versus Calcitonin in the treatment of osteoporotic vertebral pain. Curr Ther Res 1991;49:1004-10.

Somekawa Y, Chiguchi M, Ishibashi T, et al. Efficacy of ipriflavone in preventing adverse effects of leuprolide. J Clin Endocrinol Metab 2001;86:3202-6.. View abstract.

Takahashi J, Kawakatsu K, Wakayama T, Sawaoka H. Elevation of serum theophylline levels by ipriflavone in a patient with chronic obstructive pulmonary disease. Eur J Clin Pharmacol 1992;43:207-8.

Ushiroyama T, Okamura S, Ikeda A, et al. Efficacy of ipriflavone and 1 alpha vitamin D therapy for the cessation of vertebral bone loss. Int J Gynaecol Obstet 1995;48:283-8. View abstract.

Valente M, Bufalino L, Castiglione GN, et al. Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass. Calcif Tissue Int 1994;54:377-80. View abstract.

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2024 by Therapeutic Research Center, LLC. All Rights Reserved.